-
-
-
Evidence with 95-95-95 that ambitious is feasible Lancet HIV (IF 16.1) Pub Date : 2024-03-08 Mathieu Maheu-Giroux, Sharmistha Mishra
-
Progress towards the UNAIDS 95-95-95 targets in the Fifth Botswana AIDS Impact Survey (BAIS V 2021): a nationally representative survey Lancet HIV (IF 16.1) Pub Date : 2024-03-08 Madisa Mine PhD, Kristen A Stafford PhD, Rebecca L Laws PhD, Reson Marima MD, Phenyo Lekone PhD, Dinah Ramaabya BNSc, Kgomotso Makhaola PhD, Hetal K Patel MS, Prichard Mapondera MSc, Floris Wray-Gordon PhD, Chinedu Agbakwuru MD, Lillian Okui MBBS, Susan Matroos BA, Eden Onyadile MSc, Julia Ngidi BSc, Prof Alash'le Abimiku PhD, Khuteletso Bagapi MPH, Bornapate Nkomo MD, Stephane M Bodika MD, Kaylee
In 2014, UNAIDS set a goal to end the AIDS epidemic by achieving targets for the percentage of people living with HIV who were aware of their status, on antiretroviral therapy (ART), and virally suppressed. In 2020, these targets were revised to 95% for each measure (known as 95-95-95), to be reached among people living with HIV by 2025. We used data from the Fifth Botswana AIDS Impact Survey (BAIS
-
Low-cost urine tenofovir assay to triage dolutegravir resistance testing Lancet HIV (IF 16.1) Pub Date : 2024-03-07 Tyler Martinson, Jacinta Nwogu-Attah, Matthew Spinelli, Monica Gandhi
-
Uncovering HIV and malaria interactions: the latest evidence and knowledge gaps Lancet HIV (IF 16.1) Pub Date : 2024-03-05 Antía Figueroa-Romero MSc, Anna Saura-Lázaro MD, Sheila Fernández-Luis PhD, Raquel González PhD
The geographical distribution of malaria and HIV infections widely overlap in sub-Saharan Africa, constituting a complex global health challenge. The interplay between both infections raises concerns about potential immunological, clinical, and therapeutic interactions. Both diseases have been reported to exacerbate the transmission of the other, including the possible vertical transmission of HIV
-
Response to Thailand's commitment to support community-led HIV services Lancet HIV (IF 16.1) Pub Date : 2024-02-06 Nittaya Phanuphak, Surang Janyam, Pongpeera Patpeerapong, Satayu Sittikan, Kittinan Daramadhaj, Supabhorn Pengnonyang, Rena Janamnuaysook, Inthira Suya, Stephen Mills, Praphan Phanuphak
-
Thailand's commitment to support community-led HIV services Lancet HIV (IF 16.1) Pub Date : 2024-02-06 Cheewanan Lertpiriyasuwat, Suchada Jiamsiri, Plearnpit Prommali
-
Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study Lancet HIV (IF 16.1) Pub Date : 2024-01-30 Joseph J Eron, Susan J Little, Gordon Crofoot, Paul Cook, Peter J Ruane, Dushyantha Jayaweera, Laurie A VanderVeen, Edwin DeJesus, Yanan Zheng, Anthony Mills, Hailin Huang, Sarah E Waldman, Moti Ramgopal, Linda Gorgos, Sean E Collins, Jared M Baeten, Marina Caskey
Background Long-acting treatment for HIV has potential to improve adherence, provide durable viral suppression, and have long-term individual and public health benefits. We evaluated treatment with two antibodies that broadly and potently neutralise HIV (broadly neutralising antibodies; bNAbs), combined with lenacapavir, a long-acting capsid inhibitor, as a long-acting regimen. Methods This ongoing
-
Lenacapavir plus two bNAbs: feasible, with some caveats Lancet HIV (IF 16.1) Pub Date : 2024-01-30 Esteban Martinez
Abstract not available
-
HIV self-testing, PrEP, and drug resistance: some insights Lancet HIV (IF 16.1) Pub Date : 2024-01-29 Walter Ochieng, Chutima Suraratdecha
Abstract not available
-
Impact of HIV self-testing for oral pre-exposure prophylaxis scale-up on drug resistance and HIV outcomes in western Kenya: a modelling study Lancet HIV (IF 16.1) Pub Date : 2024-01-29 Sarah N Cox, Linxuan Wu, Rachel Wittenauer, Samantha Clark, D Allen Roberts, Ifechukwu Benedict Nwogu, Olga Vitruk, Alexandra P Kuo, Cheryl Johnson, Muhammad S Jamil, Anita Sands, Robin Schaefer, Christine Kisia, Rachel Baggaley, Joanne D Stekler, Adam Akullian, Monisha Sharma
Background Community-based oral pre-exposure prophylaxis (PrEP) provision has the potential to expand PrEP coverage. HIV self-testing can facilitate PrEP community-based delivery but might have lower sensitivity than facility-based HIV testing, potentially leading to inappropriate PrEP use among people with HIV and subsequent development of drug resistance. We aimed to evaluate the impact of HIV self-testing
-
Disparities in approaches to ART access in Europe Lancet HIV (IF 16.1) Pub Date : 2024-02-02 Laure Tribaudeau, Frédéric Eyvrard
Abstract not available
-
Effect of climate change on the HIV response Lancet HIV (IF 16.1) Pub Date : 2024-01-29
Abstract not available
-
A call to accelerate antiretroviral development for neonates Lancet HIV (IF 16.1) Pub Date : 2024-01-29 Aditya H Gaur, George K Siberry
Abstract not available
-
Insights on COVID-19 mortality and HIV from South Africa Lancet HIV (IF 16.1) Pub Date : 2024-01-29 Jessica E Justman, Tara F Abularrage
Abstract not available
-
Thank you to The Lancet HIV's statistical and peer reviewers in 2023 Lancet HIV (IF 16.1) Pub Date : 2024-01-29
Abstract not available
-
Paediatric abacavir–lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trial Lancet HIV (IF 16.1) Pub Date : 2024-01-29 Adrie Bekker, Nicolas Salvadori, Helena Rabie, Samantha du Toit, Kanchana Than-in-at, Marisa Groenewald, Ratchada Cressey, James Nielsen, Edmund V Capparelli, Marc Lallemant, Mark F Cotton, Tim R Cressey
Background Existing solid antiretroviral fixed-dose combination formulations are preferred over liquid formulations in children, but their suitability for neonates is unknown. We evaluated the pharmacokinetics and safety of paediatric abacavir–lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates. Methods In this open-label, two-stage, single-arm, phase 1/2
-
Trends in COVID-19 admissions and deaths among people living with HIV in South Africa: analysis of national surveillance data Lancet HIV (IF 16.1) Pub Date : 2024-01-29 Waasila Jassat, Caroline Mudara, Lovelyn Ozougwu, Richard Welch, Tracy Arendse, Maureen Masha, Lucille Blumberg, Tendesayi Kufa, Adrian Puren, Michelle Groome, Nevashan Govender, Pedro Pisa, Sharlene Govender, Ian Sanne, Heena Brahmbhatt, Lauren Parmley, Milani Wolmarans, Petro Rousseau, Anthony Selikow, Melissa Burgess, Cheryl Cohen
Background In 2021, the HIV prevalence among South African adults was 18% and more than 2 million people had uncontrolled HIV and, therefore, had increased risk of poor outcomes with SARS-CoV-2 infection. We investigated trends in COVID-19 admissions and factors associated with in-hospital COVID-19 mortality among people living with HIV and people without HIV. Methods In this analysis of national surveillance
-
Call for justice-informed HIV cure trials with ATIs Lancet HIV (IF 16.1) Pub Date : 2024-01-25 Karine Dubé, Amaya Perez-Brumer
Abstract not available
-
Closeted life of a Hollywood giant Lancet HIV (IF 16.1) Pub Date : 2024-01-25 Talha Burki
Abstract not available
-
Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies Lancet HIV (IF 16.1) Pub Date : 2024-01-24 Adam Trickey, Kathleen McGinnis, M John Gill, Sophie Abgrall, Juan Berenguer, Christoph Wyen, Mojgan Hessamfar, Peter Reiss, Katharina Kusejko, Michael J Silverberg, Arkaitz Imaz, Ramon Teira, Antonella d'Arminio Monforte, Robert Zangerle, Jodie L Guest, Vasileios Papastamopoulos, Heidi Crane, Timothy R Sterling, Sophie Grabar, Suzanne M Ingle, Jonathan A C Sterne
Background Mortality rates among people with HIV have fallen since 1996 following the widespread availability of effective antiretroviral therapy (ART). Patterns of cause-specific mortality are evolving as the population with HIV ages. We aimed to investigate longitudinal trends in cause-specific mortality among people with HIV starting ART in Europe and North America. Methods In this collaborative
-
HIV and people who inject drugs: inequality until death Lancet HIV (IF 16.1) Pub Date : 2024-01-24 Carole Seguin-Devaux
Abstract not available
-
Correction to Lancet HIV 2023; 10: e663–73 Lancet HIV (IF 16.1) Pub Date : 2024-01-22
Abstract not available
-
UK emergency department testing for HIV expanded Lancet HIV (IF 16.1) Pub Date : 2024-01-19 Tony Kirby
Abstract not available
-
Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data from a consortium of prospective cohort studies Lancet HIV (IF 16.1) Pub Date : 2024-01-12 Rachel Sacks-Davis, Daniela K van Santen, Anders Boyd, Jim Young, Ashleigh Stewart, Joseph S Doyle, Andri Rauch, Catrina Mugglin, Marina Klein, Marc van der Valk, Colette Smit, Inmaculada Jarrin, Juan Berenguer, Karine Lacombe, Maria-Bernarda Requena, Linda Wittkop, Olivier Leleux, Fabrice Bonnet, Dominique Salmon, Gail V Matthews, Jean-Paul Vincensini
Background Reinfection after successful treatment with direct-acting antivirals is hypothesised to undermine efforts to eliminate hepatitis C virus (HCV) infection among people with HIV. We aimed to assess changes in incidence of HCV reinfection among people with HIV following the introduction of direct-acting antivirals, and the proportion of all incident cases attributable to reinfection. Methods
-
Are reinfections undermining HCV elimination efforts? Lancet HIV (IF 16.1) Pub Date : 2024-01-12 David Chromy, Mattias Mandorfer
Abstract not available
-
Homophobia in the provision of sexual health care in the UK Lancet HIV (IF 16.1) Pub Date : 2024-01-11 Manik Kohli, Iain Reeves, Laura Waters
Decision making in the provision of health care is influenced by not only scientific evidence but also by the systems in which decisions are made. We consider national decisions made in the UK related to sexually transmitted infection prevention in gay, bisexual, and other men who have sex with men (GBMSM), with three specific examples—HIV pre-exposure prophylaxis, mpox (formerly known as monkeypox)
-
Difficult choices for people with HIV in the Donbas Lancet HIV (IF 16.1) Pub Date : 2024-01-08 Ed Holt
Abstract not available
-
Improving outcomes for children in families with HIV Lancet HIV (IF 16.1) Pub Date : 2023-12-21 Melissa Gladstone
Abstract not available
-
Drug consumption room comes to Glasgow Lancet HIV (IF 16.1) Pub Date : 2023-12-18 Ed Holt
Abstract not available
-
Intergenerational dialogue on HIV and ageing Lancet HIV (IF 16.1) Pub Date : 2023-12-21
Abstract not available
-
Two decades fighting two pandemics Lancet HIV (IF 16.1) Pub Date : 2023-12-21 Munyaradzi Makoni
Abstract not available
-
A community-based child health and parenting intervention to improve child HIV testing, health, and development in rural Lesotho (Early Morning Star): a cluster-randomised, controlled trial Lancet HIV (IF 16.1) Pub Date : 2023-12-21 Mark Tomlinson, Marguerite Marlow, Jackie Stewart, Moroesi Makhetha, Tholoana Sekotlo, Sebuoeng Mohale, Carl Lombard, Lynne Murray, Peter J Cooper, Nathene Morley, Stephan Rabie, Sarah Gordon, Amelia van der Merwe, Gretchen Bachman, Xanthe Hunt, Lorraine Sherr, Lucie Cluver, Sarah Skeen
Background When caregivers live in remote settings characterised by extreme poverty, poor access to health services, and high rates of HIV/AIDS, their caregiving ability and children's development might be compromised. We aimed to test the effectiveness of a community-based child health and parenting intervention to improve child HIV testing, health, and development in rural Lesotho. Methods We implemented
-
Building African HIV networks in the UK HIV response | Angelina Namiba, Charity Nyirenda, Memory Sachikonye, Rebecca Mbewe, Winnie Ssanyu Sseruma, Our Stories Told by Us: Celebrating the African Contribution to the UK HIV Response, ZZUK Press (2023), p. 256, GB£32·00 (hardcover), ISBN: 9781739462215 Lancet HIV (IF 16.1) Pub Date : 2023-12-19 Catherine Lucas
Abstract not available
-
The HIV vaccine quest: ethical and implementation challenges Lancet HIV (IF 16.1) Pub Date : 2023-12-20 Stuart Rennie
Abstract not available
-
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials Lancet HIV (IF 16.1) Pub Date : 2023-12-20 Chloe Orkin, Jean-Michel Molina, Pedro Cahn, Johannes Lombaard, Khuanchai Supparatpinyo, Sushma Kumar, Havilland Campbell, Hong Wan, Valerie Teal, Zhi Jin Xu, Ernest Asante-Appiah, Peter Sklar, Hedy Teppler, Rima Lahoulou
Background In two phase 3 trials for first-line therapy in adults with HIV-1, doravirine showed non-inferior efficacy, a favourable safety profile, and a superior lipid profile to darunavir and efavirenz through to 48 and 96 weeks. Here we report 192-week results from both studies. Methods DRIVE-FORWARD and DRIVE-AHEAD are multicentre, double-blind, randomised, active comparator-controlled, phase 3
-
Prophylactic HIV-1 vaccine trials: past, present, and future Lancet HIV (IF 16.1) Pub Date : 2023-12-20 Joseph P Nkolola, Dan H Barouch
An effective HIV-1 vaccine is a global health priority but has remained elusive for more than 40 years. Key scientific hurdles that have hampered vaccine development are the unprecedented genetic variability of the virus, the rapid establishment of persistent viral latency, and the challenges associated with induction of broadly neutralising antibodies. Clinical trials have been instrumental in evaluating
-
The best place for doravirine Lancet HIV (IF 16.1) Pub Date : 2023-12-20 Cristina Mussini, Giovanni Guaraldi
Abstract not available
-
Living authentically despite prejudice and marginalisation Lancet HIV (IF 16.1) Pub Date : 2023-12-18 Talha Burki
Abstract not available
-
Survival by sex and HIV status in patients with anal cancer in the USA between 2001 and 2019: a retrospective cohort study Lancet HIV (IF 16.1) Pub Date : 2023-12-08 Jaimie Z Shing, Eric A Engels, April A Austin, Megan A Clarke, Jennifer H Hayes, Aimée R Kreimer, Analise Monterosso, Marie-Josèphe Horner, Karen S Pawlish, Qianlai Luo, Elizabeth R Zhang, Aimee J Koestler, Ruth M Pfeiffer, Meredith S Shiels
Background The risk of anal cancer is increased among people with HIV, particularly men who have sex with men. Estimating survival by HIV status and sex and identifying groups at high risk is crucial for documenting prognostic differences between populations. We aimed to compare all-cause and anal cancer-specific survival in patients with anal cancer with and without HIV, stratified by sex, and to
-
Expanding early detection of anal cancer to improve survival Lancet HIV (IF 16.1) Pub Date : 2023-12-08 Rebecca G Nowak
Abstract not available
-
Transitional community adherence support for people leaving incarceration in South Africa: a pragmatic, open-label, randomised controlled trial Lancet HIV (IF 16.1) Pub Date : 2023-12-07 Tonderai Mabuto, Daniel M Woznica, Pretty Ndini, Derrick Moyo, Munazza Abraham, Colleen Hanrahan, Salome Charalambous, Barry Zack, Stefan Baral, Jill Owczarzak, Christopher J Hoffmann
Background People released from correctional facilities face multifactorial barriers to continuing HIV treatment. We hypothesised that barriers faced in the first 6 months of community re-entry would be decreased by a multilevel group-based and peer-led intervention, the Transitional Community Adherence Club (TCAC). Methods We did a pragmatic, open-label, individually randomised controlled trial in
-
The power of peers at prison exit Lancet HIV (IF 16.1) Pub Date : 2023-12-07 Anne C Spaulding
Abstract not available
-
HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study Lancet HIV (IF 16.1) Pub Date : 2023-12-04 Deborah Persaud, Yvonne Bryson, Bryan S Nelson, Camlin Tierney, Mark F Cotton, Anne Coletti, Jennifer Jao, Stephen A Spector, Mark Mirochnick, Edmund V Capparelli, Diane Costello, Joseph Szewczyk, Nicol Nicodimus, Lynda Stranix-Chibanda, Adeodata R Kekitiinwa, Violet Korutaro, Christina Reding, Mary N Carrington, Sai Majji, Dwight E Yin, Ellen G Chadwick
Background Infants born with HIV-1 require lifelong antiretroviral therapy (ART). We aimed to assess whether very early ART in neonates might restrict HIV-1 reservoirs, an important step towards ART-free remission. Methods IMPAACT P1115 is an ongoing, phase 1/2, proof-of-concept study in which infants were enrolled at 30 research clinics in 11 countries (Brazil, Haiti, Kenya, Malawi, South Africa,
-
Super early treatment for HIV acquired in utero Lancet HIV (IF 16.1) Pub Date : 2023-12-04 Philippe Van de Perre, Penny L Moore
Abstract not available
-
Making the most of a fertile PrEP landscape Lancet HIV (IF 16.1) Pub Date : 2023-11-29
Abstract not available
-
Planning for PrEP: are national surveillance data sufficient? Lancet HIV (IF 16.1) Pub Date : 2023-11-29 Sarah E Rutstein, William C Miller
Abstract not available
-
ART and cardiovascular-disease risk in people with HIV Lancet HIV (IF 16.1) Pub Date : 2023-11-29 Carlos Malvestutto
Abstract not available
-
Highlights of the 19th European AIDS Conference Lancet HIV (IF 16.1) Pub Date : 2023-11-29 Adrian Gonzalez-Lopez, Peter Hayward
Abstract not available
-
PrEP empowering female sex workers in Kenya Lancet HIV (IF 16.1) Pub Date : 2023-11-29 Christabel Ligami
Abstract not available
-
LVCT Health: implementing PrEP in Kenya Lancet HIV (IF 16.1) Pub Date : 2023-11-29 Christabel Ligami
Abstract not available
-
HIV pre-exposure prophylaxis and its implementation in the PrEP Impact Trial in England: a pragmatic health technology assessment Lancet HIV (IF 16.1) Pub Date : 2023-11-29 Ann K Sullivan, John Saunders, Monica Desai, Andrea Cartier, Holly D Mitchell, Sajjida Jaffer, Dana Ogaz, Chiara Chiavenna, Andre Charlett, Victor Diamente, Rainer Golombek, Kaveh Manavi, Cecilia Priestley, Laura J Waters, Ana Milinkovic, Alan McOwan, Claudia Estcourt, Caroline A Sabin, Alison Rodger, Deborah Gold, O Noel Gill
Background HIV pre-exposure prophylaxis (PrEP) is highly effective in preventing HIV acquisition. To enable routine commissioning of PrEP in England, we aimed to establish population need, duration of need, PrEP uptake, and duration of use in attendees of sexual health services (SHS) in England. Methods The Impact Trial was a prospective, open-label, single-arm, multicentre trial conducted at 157 SHS
-
Effect of implementation strategies on pre-exposure prophylaxis persistence among female sex workers in South Africa: an interrupted time series study Lancet HIV (IF 16.1) Pub Date : 2023-11-29 Amrita Rao, Hlengiwe Mhlophe, Anje Pretorius, Mfezi Mcingana, Jennifer Mcloughlin, Lillian Shipp, Stefan Baral, Harry Hausler, Sheree Schwartz, Catherine Lesko
Background A disproportionate number of new HIV infections in South Africa are among female sex workers; pre-exposure prophylaxis (PrEP) for HIV prevention is freely available to female sex workers in the country, but unique barriers challenge PrEP persistence. TB HIV Care, a large South African non-profit organisation that provides daily oral PrEP (tenofovir disoproxil fumarate and emtricitabine)
-
Ageism: the -ism affecting the lives of older people living with HIV Lancet HIV (IF 16.1) Pub Date : 2023-11-28 Giovanni Guaraldi, Jovana Milic, Mario Cascio, Cristina Mussini, Esteban Martinez, Jules Levin, Daniele Calzavara, Rebecca Mbewe, Julian Falutz, Chloe Orkin, Matteo Cesari, Jeffrey V Lazarus
WHO defines ageism as stereotypes, prejudice, and discrimination based on age. Ageism is a multidimensional concept that encompasses multiple components related to the individual, the social group, and the institution in different cultural and environmental settings. In people ageing with HIV these elements include self-stigma, discrimination in society, and experiences in care, many of which are unique
-
Correction to Lancet HIV 2023; 10: e713–22 Lancet HIV (IF 16.1) Pub Date : 2023-11-20
Abstract not available
-
Long-acting cabotegravir PrEP: a time for cautious optimism Lancet HIV (IF 16.1) Pub Date : 2023-11-09 David WJ Griffin, Jennifer F Hoy, James H McMahon
Abstract not available
-
Post-exposure prophylaxis to prevent HIV: new drugs, new approaches, and more questions Lancet HIV (IF 16.1) Pub Date : 2023-11-09 Kenneth H Mayer, Lao-Tzu Allan-Blitz
Post-exposure prophylaxis (PEP) to prevent HIV acquisition has been recommended for over three decades, but remains underutilised. Over the past decade, clinical trials have established the safety and tolerability of newer PEP regimens, particularly those containing integrase strand transfer inhibitors (INSTIs) combined with a tenofovir and lamivudine or emtricitabine backbone. Several of these regimens
-
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial Lancet HIV (IF 16.1) Pub Date : 2023-11-09 Raphael J Landovitz, Brett S Hanscom, Meredith E Clement, Ha V Tran, Esper G Kallas, Manya Magnus, Omar Sued, Jorge Sanchez, Hyman Scott, Joe J Eron, Carlos del Rio, Sheldon D Fields, Mark A Marzinke, Susan H Eshleman, Deborah Donnell, Matthew A Spinelli, Ryan M Kofron, Richard Berman, Estelle M Piwowar-Manning, Paul A Richardson, Beatriz Grinsztejn
Background Injectable cabotegravir was superior to daily oral tenofovir disoproxil fumarate plus emtricitabine for HIV prevention in two clinical trials. Both trials had the primary aim of establishing the HIV prevention efficacy of long-acting injectable cabotegravir pre-exposure prophylaxis (PrEP) compared with tenofovir disoproxil fumarate plus emtricitabine daily oral PrEP. Long-acting PrEP was
-
Programme science: a route to effective coverage and population-level impact for HIV and sexually transmitted infection prevention Lancet HIV (IF 16.1) Pub Date : 2023-11-06 Leigh M McClarty, Marissa L Becker, Patricia J García, Geoff P Garnett, Gina A Dallabetta, Helen Ward, Sevgi O Aral, James F Blanchard
Improvements in context-specific programming are essential to address HIV and other sexually transmitted and blood-borne infection epidemics globally. A programme science approach emphasises the need for context-specific evidence and knowledge, generated on an ongoing basis, to inform timely and appropriate programmatic decisions. We aim to accelerate and improve the use of embedded research, inquiry